Neurocrine presents data from long term use of INGREZZA

Neurocrine Biosciences announced it will present data analyzing the long-term outcomes of treating tardive dyskinesia with INGREZZA capsules in older and elderly patients from two studies. These data are being presented at the American Association for Geriatric Psychiatry 2023 Annual Meeting from March 3-6 in New Orleans. The data demonstrated that long-term treatment with once-daily INGREZZA led to clinically meaningful reductions of TD symptoms in both older patients with TD and elderly patients. At 48 weeks of INGREZZA treatment, greater than 80% of participants in the greater than or equal to 65 years age group met the greater than 50% improvement in the Abnormal Involuntary Movement Scale response threshold. Analyses included the following: Mean change from baseline in AIMS total score; Percentage of patients meeting AIMS response thresholds, including greater than or equal to 50% improvement from baseline and greater than or equal to 70% improvement from baseline; Global response thresholds, including Clinical Global Impression of Change-Tardive Dyskinesia and Patient Global Impression of Change defined as "much improved" or "very much improved." Similar results were found in the greater than or equal to 55 years age group. Mean changes from baseline to week 48 in psychiatric symptom scale scores were minimal, indicating maintenance of psychiatric stability in both age groups.